Market capitalization | GBP34.28b |
Enterprise Value | GBP42.71b |
P/E (TTM) P/E ratio | 32.00 |
EV/FCF (TTM) EV/FCF | 26.14 |
EV/Sales (TTM) EV/Sales | 3.79 |
P/S ratio (TTM) P/S ratio | 3.04 |
P/B ratio (TTM) P/B ratio | 2.08 |
Dividend yield | 1.11% |
Last dividend (FY23) | GBP0.04 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
18 Analysts have issued a Haleon forecast:
18 Analysts have issued a Haleon forecast:
Jun '24 |
+/-
%
|
||
Revenue | 11,258 11,258 |
1%
1%
|
|
Gross Profit | 6,804 6,804 |
2%
2%
|
|
EBITDA | 2,625 2,625 |
7%
7%
|
EBIT (Operating Income) EBIT | 2,315 2,315 |
8%
8%
|
Net Profit | 1,088 1,088 |
12%
12%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Haleon Plc provides personal healthcare products. The firm focus on consumer healthcare and driven by its purpose of delivering better everyday health with humanity. Its brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. The company is headquartered in Brentford, the United Kingdom.
Head office | United Kingdom |
CEO | Brian McNamara |
Founded | 2021 |
Website | www.haleon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.